Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fisogatinib + Sugemalimab in HCC
NCT04194801Phase 2Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of fisogatinib, sugemalimab in hepatocellular carcinoma (HCC), sponsored by CStone Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
fisogatinibsugemalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04194801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194801.